[
    [
        {
            "time": "",
            "original_text": "健帆生物(300529)：肾病业务维持高增长 重症业务表现亮眼",
            "features": {
                "keywords": [
                    "健帆生物",
                    "肾病业务",
                    "高增长",
                    "重症业务",
                    "表现亮眼"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物(300529)：肾病业务维持高增长 重症业务表现亮眼",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "健帆生物中报点评：业绩持续高增长，疫情推动海外销售！【东吴医药朱国广团队】",
            "features": {
                "keywords": [
                    "健帆生物",
                    "中报",
                    "业绩高增长",
                    "疫情",
                    "海外销售"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物中报点评：业绩持续高增长，疫情推动海外销售！【东吴医药朱国广团队】",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "健帆生物(300529)2020年中报点评：业绩符合预期 疫情助力品牌影响力提升",
            "features": {
                "keywords": [
                    "健帆生物",
                    "中报",
                    "业绩符合预期",
                    "疫情",
                    "品牌影响力提升"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物(300529)2020年中报点评：业绩符合预期 疫情助力品牌影响力提升",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "健帆生物(300529)：业绩快速增长持续 符合市场预期",
            "features": {
                "keywords": [
                    "健帆生物",
                    "业绩快速增长",
                    "市场预期"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物(300529)：业绩快速增长持续 符合市场预期",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "健帆生物(300529)：肾病肝病新冠三线放量 销售费用比例下行",
            "features": {
                "keywords": [
                    "健帆生物",
                    "肾病",
                    "肝病",
                    "新冠",
                    "三线放量",
                    "销售费用比例下行"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物(300529)：肾病肝病新冠三线放量 销售费用比例下行",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "【国金晨讯】建发国际:优秀国资房企,有望冲击千亿规模；从“黑悟空到原神”,手游美术工艺看中国；上调中国巨石盈利预测",
            "features": {
                "keywords": [
                    "建发国际",
                    "国资房企",
                    "千亿规模",
                    "手游",
                    "美术工艺",
                    "中国巨石",
                    "盈利预测"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "房地产",
                    "游戏",
                    "建材"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国金晨讯】建发国际:优秀国资房企,有望冲击千亿规模；从“黑悟空到原神”,手游美术工艺看中国；上调中国巨石盈利预测",
                "Correlation": 1,
                "Sentiment": 5,
                "Importance": 3,
                "Impact": 2,
                "Duration": 2,
                "Entity_Density": 1,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]